Ubi Titer Issue #8
In Vivo Antibody Click, Masked Cytokines, and Antibody Developability at Scale
Conditional and combinatorial targeting dominates this week: drugs assembled or unmasked only where two signals coincide, and large-scale structural data correcting the design rules underneath all of it.
- antibody-drug conjugates
- bioorthogonal click chemistry
- masked cytokines
- VHH / nanobody
- bispecific antibodies
- antibody developability
- N-linked glycosylation
- quantitative systems pharmacology
Paper 1 · Nature
Modular in vivo antibody–ADC click to reverse drug resistance in tumours
Sequentially dosed antibody-TCO and ADC-tetrazine conjugates ligate inside the tumor via click chemistry, lifting trastuzumab uptake in HER2-ultralow tumors 3.2-fold and driving complete remissions in models that resist conventional ADCs.
Core finding
A bioorthogonal ligation strategy administers an antibody carrying a trans-cyclooctene handle and an ADC carrying a tetrazine handle separately, letting them couple in vivo through an inverse-electron-demand Diels-Alder reaction that completes in under 30 minutes. In HER2-ultralow tumors, click conditions raised trastuzumab accumulation 3.2-fold (31.63 versus 11.90 %ID/g), produced 100% complete remission in HER2-positive NCIN87 tumors, 50% complete response in HER2-low immunocompetent models, and responses in 5 of 9 previously T-DXd-refractory tumors that had upregulated EGFR.
What is novel
It achieves dual-antigen engagement without engineering a bispecific. Pairing FDA-approved antibodies (trastuzumab, panitumumab, pertuzumab) and approved payloads (T-DXd, T-DM1) through modular click handles lets a two-component system address antigen heterogeneity, and site-specific conjugation on Fc glycans cut hepatic accumulation two-fold versus random lysine labeling.
Limitations
Simultaneous systemic and tumor-site click reactions make it hard to cleanly separate receptor-mediated uptake from antibody clustering or altered pharmacokinetics; work is preclinical only, DXd-associated lung toxicity is unaddressed, and the proof of concept is confined to the HER2/EGFR axis.
Why it matters in context
This builds on a decade of bioorthogonal pretargeting work, mostly used for imaging, and repurposes it as an in-tumor drug-assembly step. It offers a lower-engineering-cost route to the multi-target coverage that bispecific ADCs pursue, and slots alongside the field's growing interest in overcoming antigen heterogeneity and acquired ADC resistance.
Paper 2 · mAbs
Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate
A dual-specificity switch arm keeps IL-12 masked in circulation and unveils it only where the tumor matrix antigen FN-EDB competes it off, a trans-activation logic gate tuned with a QSP model and validated in cell assays.
Core finding
Switch-IL-12 is a reversible antibody format built from a switch arm that competitively binds either a tethered single-chain IL-12 or the pan-tumor matrix antigen Fibronectin extra-domain B (FN-EDB), plus a separate FN-EDB targeting arm that drives avidity. In the absence of FN-EDB the IL-12 stays masked; when FN-EDB is present it out-competes the cytokine and unveils it. Phage display and rational library design produced a lead switch arm (Switch2) binding IL-12 at 0.33 nM and FN-EDB at 250 nM, and cell assays confirmed FN-EDB-dependent IFN-gamma release from IL-12-receptor-bearing NK-92 cells.
What is novel
Most dual-Fab logic gates to date use cis-activation, where binding a receptor on a target cell unveils a ligand for a second receptor on the same cell. This is a trans-activation gate: activation is gated by a soluble/matrix antigen rather than a same-cell receptor, and a quantitative systems pharmacology model was used up front to define the binding affinities required for a positive therapeutic window before molecules were built.
Limitations
Efficacy is shown as in vitro IFN-gamma release and QSP-projected receptor occupancy, not in vivo tumor control; human IL-12 does not cross-react with the mouse receptor, so the team relied on modeling rather than mouse efficacy. In vitro FN-EDB concentrations were roughly 100-fold below tumor levels, and the higher-affinity switch arm only unmasked at elevated concentrations.
Why it matters in context
It joins an active wave of conditionally activated cytokines and masked biologics aimed at widening the notoriously narrow IL-12 therapeutic window, and demonstrates QSP-guided antibody engineering, using a mechanistic model to set target affinities rather than screening blindly, which is increasingly how sophisticated switch molecules are designed.
Paper 3 · mAbs
Glycosylation penetrance of N-X-S/T sequons in antibody variable domains: a structural survey of 19,265 human antibody structures reassessing the histidine/glutamine suppression hypothesis
Across 19,265 antibody structures, variable-domain N-glycosylation shows up at only 7.82%, about half the rate from prior enriched datasets; glutamine at the sequon X-position is not a suppressor after all, and N-X-T sequons are 3.84-fold more likely to be glycosylated than N-X-S.
Core finding
A structural survey of 19,265 human antibody structures identified 1,368 N-X-S/T glycosylation sequons in variable domains and found N-glycosylation occupied at an observed penetrance of just 7.82% (107/1,368; Wilson 95% CI 6.5-9.4%), roughly half the 16.47% reported from an earlier glycosylation-enriched corpus. Occupancy depends sharply on the sequon's composition: histidine, lysine, and tryptophan at the X-position (the middle residue of N-X-S/T) showed zero observed glycosylation, and the third position matters too, with N-X-T sequons glycosylated 3.84-fold more often than N-X-S (13.64% vs 3.55%).
What is novel
The N-linked sequon is Asn-X-Ser/Thr, where X is any residue except proline and the enzyme oligosaccharyltransferase attaches glycan to the asparagine. Two long-standing design rules get corrected here. First, glutamine at the X-position was previously classified as a glycosylation suppressor, but with 6.45% penetrance (2/31) it is statistically indistinguishable from the 7.82% baseline, so the residues genuinely associated with suppression are histidine, lysine, and tryptophan, not glutamine. Second, the identity of the third residue is a strong, prior-stable effect: threonine-terminated sequons (N-X-T) are far more likely to actually be glycosylated than serine-terminated ones (N-X-S), so treating S and T as equivalent liabilities overcounts risk for N-X-S and undercounts it for N-X-T. The paper packages these into a sequence-only decision tree for triaging machine-designed antibody candidates.
Limitations
Crystallographic detection is a lower bound because disordered or unresolved glycans leave no density, so the true rate may be somewhat higher, and PDB deposition bias toward well-behaved, often non-glycosylated constructs likely persists even after correcting for the enriched corpus. The per-residue X-position counts are also small (for example only 31 glutamine sequons), so those specific estimates carry wide confidence intervals.
Why it matters in context
As de novo and machine-learning antibody design pipelines (the paper explicitly targets tools like RFdiffusion) increasingly screen candidate sequences for developability liabilities up front, the sequon-occupancy priors those tools rely on matter directly; this recalibrates a widely used heuristic against a far larger structural evidence base and gives a concrete, position-aware triage rule rather than a flat flag on every sequon.
Paper 4 · Antibody Therapeutics
Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers
One antibody against the GI-cancer antigen CDH17 is deployed two ways, as an MMAE/MMAF ADC and as a bispecific engaging a rare pan-Vδ1/Vδ2 gamma-delta T-cell agonist nanobody, exploiting the abundance of gamma-delta T cells in gut epithelium.
Core finding
TAVO307, a monoclonal antibody binding CDH17 (cadherin-17) with picomolar affinity (46 pM by ELISA), was developed as complementary modalities. As an ADC with MMAF or MMAE payloads it killed GI cancer lines at 16.5-197 pM and inhibited xenograft growth 67-95%. Paired with VHH371, a rare pan-gamma-delta TCR agonist nanobody, it formed a T-cell engager that triggered gamma-delta T-cell degranulation against tumor cells, further boosted by an attenuated IL-15 fusion.
What is novel
VHH371 is an unusual antibody that activates both Vδ1 and Vδ2 gamma-delta T-cell subsets, addressing the subset heterogeneity that has limited gamma-delta cell therapy, and the work pairs that immune-engager modality with a cytotoxic ADC against the same GI-selective target, exploiting gamma-delta T cells' natural abundance in gut epithelium.
Limitations
All data are preclinical; the ADC's toxicity profile against normal intestinal epithelium is not yet established, IL-15/proliferation data come from limited PBMC donors, and the TCE shows a hook effect (loss of activity at high concentration) that will require careful dose optimization.
Why it matters in context
CDH17 is an emerging GI-cancer target, and this positions two mechanistically distinct modalities against it at once; the pan-subset gamma-delta engager is notable amid broad current interest in gamma-delta T cells as an allogeneic, tissue-resident alternative to alpha-beta T-cell engagers.
Paper 5 · Clinical Cancer Research
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
A monovalent PD-1/CTLA-4 bispecific engineered to steer CTLA-4 blockade onto PD-1-positive T cells reported first-in-human data in 86 patients: 19.8% objective response, 17.5-month median duration, and T-cell activation beyond approved combination regimens.
Core finding
Volrustomig, an IgG1 monovalent bispecific that provides durable PD-1 blockade while preferentially engaging CTLA-4 on PD-1-positive T cells, was evaluated in a first-in-human phase 1 study (NCT03530397) across 2.25 to 2,500 mg IV every three weeks in patients with advanced solid tumors. Among 86 patients in the dose-exploration and immunotherapy-naive expansion cohorts, 17 (19.8%) had objective responses including 2 complete responses, with a median response duration of 17.5 months; at doses of 500 mg and above, the antibody drove peripheral and intratumoral T-cell activation exceeding that of approved PD-1/CTLA-4 regimens.
What is novel
The monovalent, preferential-engagement design aims to concentrate CTLA-4 blockade onto the already PD-1-engaged (exhausted, tumor-reactive) T-cell subset rather than blocking CTLA-4 systemically, an attempt to widen the therapeutic index relative to combining separate anti-PD-1 and anti-CTLA-4 antibodies.
Limitations
This is early dose-exploration and expansion data; efficacy signals are preliminary and uncontrolled, and long-term safety and durability of response are not yet established.
Why it matters in context
Dual PD-1/CTLA-4 blockade is clinically validated but limited by the toxicity of free-combination checkpoint inhibition; volrustomig is one of several next-generation bispecific designs attempting to retain the efficacy of the combination while spatially restricting CTLA-4 engagement to lower systemic toxicity.
Paper 6 · Journal of Pharmacokinetics and Pharmacodynamics
QSP model for AAV-mediated antibody delivery in rat brain
A mechanistic model jointly tracks AAV vector, expressed antibody, target antigen, and antibody-target complex across brain subregions, predicting that intra-cisterna magna or intrastriatal delivery beats high-dose IV for CNS target engagement.
Core finding
A quantitative systems pharmacology model integrates AAV vector, brain, and monoclonal-antibody PBPK sub-models to track the vector, the antibody it expresses, the target antigen, and the antibody-target complex across plasma, peripheral tissue, and brain subregions (CSF and interstitial fluid). It predicts that intra-cisterna magna injection at a medium AAV dose, or intrastriatal injection at a low dose, achieves better CNS target engagement with less systemic exposure than high-dose intravenous administration of AAV encoding a CNS-targeted antibody.
What is novel
It is the first model to jointly describe vector, gene-delivered antibody, target, and complex disposition across brain subregions for AAV-delivered antibody therapeutics, a modality distinct from directly dosed antibodies and one that few PK/PD frameworks currently capture.
Limitations
It is built on rat data and a single undisclosed target/antibody system, so translation to human dosing carries substantial uncertainty, compounded by the known difficulty of projecting first-in-human AAV doses.
Why it matters in context
As gene-delivered biologics for CNS disease advance, mechanistic models that connect route of administration to regional brain exposure become decision-support tools; this extends established antibody PBPK modeling to the added complexity of vector transduction and in situ antibody expression.
Paper 7 · bioRxiv
Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting
One anti-FAP nanobody engineered into three formats maps how valency and molecular weight trade off in PET imaging: the monomer clears fast, the low-MW bivalent dimer maximizes tumor-to-blood ratio, and the Fc-fusion gives the highest, most durable uptake.
Core finding
An affinity-matured anti-FAP VHH (F7) was built into a monomer, a low-molecular-weight tethered bivalent dimer (F7D), and an Fc-fusion (F7-Fc), with both bivalent constructs reaching picomolar affinity (29 pM and 38 pM by BLI). PET imaging in FAP-positive prostate cancer xenografts showed strongly format-dependent behavior: the monomer had rapid uptake and clearance with tumor uptake roughly two-fold above the small-molecule benchmark FAPI-46; F7D reached a tumor-to-blood ratio of about 4.3 at 24 hours; and F7-Fc gave the highest tumor uptake (roughly 10-15 %ID/g), enabling longitudinal imaging out to 144 hours with tumor-selective absorbed dose.
What is novel
It systematically compares valency and molecular-weight tuning within a single VHH binder against one target, directly mapping construct format to pharmacokinetic and imaging tradeoffs rather than reporting a single-format proof of concept, producing usable design rules for FAP-targeted theranostics.
Limitations
This is a preprint reporting preclinical imaging in one xenograft model; the monomer showed very high kidney retention (about 39 %ID/g), therapeutic (as opposed to imaging) payload data are not included, and human translation is untested.
Why it matters in context
FAP is an attractive stromal target across solid tumors where small-molecule FAPI radiotracers suffer rapid washout; this shows camelid single-domain scaffolds can be format-tuned to trade clearance speed against tumor retention, informing the broader move toward biologic FAP radioligands.
Primary papers
- [1] Modular in vivo antibody–ADC click to reverse drug resistance in tumours (Nature)
- [2] Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate (mAbs)
- [3] Glycosylation penetrance of N-X-S/T sequons in antibody variable domains: a structural survey of 19,265 human antibody structures reassessing the histidine/glutamine suppression hypothesis (mAbs)
- [4] Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers (Antibody Therapeutics)
- [5] Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody (Clinical Cancer Research)
- [6] QSP model for AAV-mediated antibody delivery in rat brain (Journal of Pharmacokinetics and Pharmacodynamics)
- [7] Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting (bioRxiv)